Cargando…
Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
AIMS: To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] wit...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288745/ https://www.ncbi.nlm.nih.gov/pubmed/36255281 http://dx.doi.org/10.1002/ehf2.13964 |
_version_ | 1784748515398778880 |
---|---|
author | Gimeno, Juan R. Olivotto, Iacopo Rodríguez, Ana Isabel Ho, Carolyn Y. Fernández, Adrián Quiroga, Alejandro Espinosa, Mari Angeles Gómez‐González, Cristina Robledo, María Tojal‐Sierra, Lucas Day, Sharlene M. Owens, Anjali Barriales‐Villa, Roberto Larrañaga, Jose María Rodríguez‐Palomares, Jose González‐del‐Hoyo, Maribel Piqueras‐Flores, Jesús Reza, Nosheen Chumakova, Olga Ashley, Euan A. Parikh, Victoria Wheeler, Matthew Jacoby, Daniel Pereira, Alexandre C. Saberi, Sara Helms, Adam S. Villacorta, Eduardo Gallego‐Delgado, María de Castro, Daniel Domínguez, Fernando Ripoll‐Vera, Tomás Zorio‐Grima, Esther Sánchez‐Martínez, José Carlos García‐Álvarez, Ana Arbelo, Elena Mogollón, María Victoria Fuentes‐Cañamero, María Eugenia Grande, Elias Peña, Carlos Monserrat, Lorenzo Lakdawala, Neal K. |
author_facet | Gimeno, Juan R. Olivotto, Iacopo Rodríguez, Ana Isabel Ho, Carolyn Y. Fernández, Adrián Quiroga, Alejandro Espinosa, Mari Angeles Gómez‐González, Cristina Robledo, María Tojal‐Sierra, Lucas Day, Sharlene M. Owens, Anjali Barriales‐Villa, Roberto Larrañaga, Jose María Rodríguez‐Palomares, Jose González‐del‐Hoyo, Maribel Piqueras‐Flores, Jesús Reza, Nosheen Chumakova, Olga Ashley, Euan A. Parikh, Victoria Wheeler, Matthew Jacoby, Daniel Pereira, Alexandre C. Saberi, Sara Helms, Adam S. Villacorta, Eduardo Gallego‐Delgado, María de Castro, Daniel Domínguez, Fernando Ripoll‐Vera, Tomás Zorio‐Grima, Esther Sánchez‐Martínez, José Carlos García‐Álvarez, Ana Arbelo, Elena Mogollón, María Victoria Fuentes‐Cañamero, María Eugenia Grande, Elias Peña, Carlos Monserrat, Lorenzo Lakdawala, Neal K. |
author_sort | Gimeno, Juan R. |
collection | PubMed |
description | AIMS: To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS‐Cov‐2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS‐CoV‐2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty‐nine (22.9%) HCM patients were hospitalized for non‐ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS‐CoV‐2‐related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one‐unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community‐based SARS‐CoV‐2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600). CONCLUSIONS: Over one‐fourth of HCM patients infected with SARS‐Cov‐2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality. |
format | Online Article Text |
id | pubmed-9288745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92887452022-07-19 Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry Gimeno, Juan R. Olivotto, Iacopo Rodríguez, Ana Isabel Ho, Carolyn Y. Fernández, Adrián Quiroga, Alejandro Espinosa, Mari Angeles Gómez‐González, Cristina Robledo, María Tojal‐Sierra, Lucas Day, Sharlene M. Owens, Anjali Barriales‐Villa, Roberto Larrañaga, Jose María Rodríguez‐Palomares, Jose González‐del‐Hoyo, Maribel Piqueras‐Flores, Jesús Reza, Nosheen Chumakova, Olga Ashley, Euan A. Parikh, Victoria Wheeler, Matthew Jacoby, Daniel Pereira, Alexandre C. Saberi, Sara Helms, Adam S. Villacorta, Eduardo Gallego‐Delgado, María de Castro, Daniel Domínguez, Fernando Ripoll‐Vera, Tomás Zorio‐Grima, Esther Sánchez‐Martínez, José Carlos García‐Álvarez, Ana Arbelo, Elena Mogollón, María Victoria Fuentes‐Cañamero, María Eugenia Grande, Elias Peña, Carlos Monserrat, Lorenzo Lakdawala, Neal K. ESC Heart Fail Original Articles AIMS: To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS‐Cov‐2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS‐CoV‐2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty‐nine (22.9%) HCM patients were hospitalized for non‐ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS‐CoV‐2‐related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one‐unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community‐based SARS‐CoV‐2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600). CONCLUSIONS: Over one‐fourth of HCM patients infected with SARS‐Cov‐2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality. John Wiley and Sons Inc. 2022-06-03 /pmc/articles/PMC9288745/ /pubmed/36255281 http://dx.doi.org/10.1002/ehf2.13964 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Gimeno, Juan R. Olivotto, Iacopo Rodríguez, Ana Isabel Ho, Carolyn Y. Fernández, Adrián Quiroga, Alejandro Espinosa, Mari Angeles Gómez‐González, Cristina Robledo, María Tojal‐Sierra, Lucas Day, Sharlene M. Owens, Anjali Barriales‐Villa, Roberto Larrañaga, Jose María Rodríguez‐Palomares, Jose González‐del‐Hoyo, Maribel Piqueras‐Flores, Jesús Reza, Nosheen Chumakova, Olga Ashley, Euan A. Parikh, Victoria Wheeler, Matthew Jacoby, Daniel Pereira, Alexandre C. Saberi, Sara Helms, Adam S. Villacorta, Eduardo Gallego‐Delgado, María de Castro, Daniel Domínguez, Fernando Ripoll‐Vera, Tomás Zorio‐Grima, Esther Sánchez‐Martínez, José Carlos García‐Álvarez, Ana Arbelo, Elena Mogollón, María Victoria Fuentes‐Cañamero, María Eugenia Grande, Elias Peña, Carlos Monserrat, Lorenzo Lakdawala, Neal K. Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
title | Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
title_full | Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
title_fullStr | Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
title_full_unstemmed | Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
title_short | Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
title_sort | impact of sars‐cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288745/ https://www.ncbi.nlm.nih.gov/pubmed/36255281 http://dx.doi.org/10.1002/ehf2.13964 |
work_keys_str_mv | AT gimenojuanr impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT olivottoiacopo impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT rodriguezanaisabel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT hocarolyny impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT fernandezadrian impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT quirogaalejandro impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT espinosamariangeles impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT gomezgonzalezcristina impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT robledomaria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT tojalsierralucas impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT daysharlenem impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT owensanjali impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT barrialesvillaroberto impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT larranagajosemaria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT rodriguezpalomaresjose impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT gonzalezdelhoyomaribel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT piquerasfloresjesus impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT rezanosheen impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT chumakovaolga impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT ashleyeuana impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT parikhvictoria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT wheelermatthew impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT jacobydaniel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT pereiraalexandrec impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT saberisara impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT helmsadams impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT villacortaeduardo impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT gallegodelgadomaria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT decastrodaniel impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT dominguezfernando impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT ripollveratomas impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT zoriogrimaesther impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT sanchezmartinezjosecarlos impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT garciaalvarezana impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT arbeloelena impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT mogollonmariavictoria impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT fuentescanameromariaeugenia impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT grandeelias impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT penacarlos impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT monserratlorenzo impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT lakdawalanealk impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry AT impactofsarscov2infectioninpatientswithhypertrophiccardiomyopathyresultsofaninternationalmulticentreregistry |